Histiocytic Disorders, Malignant clinical trials at UCSF

1 research study open to eligible people

UCSF is a research hospital studying malignant histiocytic disorders, rare cancers that affect certain immune cells. UCSF studies cobimetinib in adults and children with Langerhans cell histiocytosis. The studies assess safety, side effects, and how the drug works.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Our lead scientists for Histiocytic Disorders, Malignant research studies include .

Last updated: